Cytosorbents (NASDAQ:CTSO) Now Covered by StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report issued on Tuesday. The brokerage set a “hold” rating on the medical research company’s stock.

CTSO has been the topic of several other reports. EF Hutton Acquisition Co. I raised shares of Cytosorbents to a “strong-buy” rating in a research note on Monday, July 29th. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a report on Monday, November 11th.

Cytosorbents Stock Up 1.1 %

CTSO opened at $0.93 on Tuesday. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. The business’s fifty day simple moving average is $1.11 and its 200 day simple moving average is $1.01. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $2.15. The stock has a market cap of $50.85 million, a PE ratio of -2.58 and a beta of 0.56.

Hedge Funds Weigh In On Cytosorbents

Several institutional investors and hedge funds have recently bought and sold shares of CTSO. CM Management LLC boosted its stake in shares of Cytosorbents by 3.0% during the second quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock valued at $598,000 after purchasing an additional 25,000 shares during the period. Geode Capital Management LLC raised its holdings in Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after buying an additional 32,415 shares during the last quarter. Atomi Financial Group Inc. purchased a new stake in Cytosorbents during the 3rd quarter valued at $51,000. Finally, Sargent Investment Group LLC grew its holdings in Cytosorbents by 4.9% in the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after acquiring an additional 67,181 shares during the last quarter. 32.87% of the stock is currently owned by institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.